OA11010A - Quinoline derivatives - Google Patents

Quinoline derivatives Download PDF

Info

Publication number
OA11010A
OA11010A OA9800061A OA9800061A OA11010A OA 11010 A OA11010 A OA 11010A OA 9800061 A OA9800061 A OA 9800061A OA 9800061 A OA9800061 A OA 9800061A OA 11010 A OA11010 A OA 11010A
Authority
OA
OAPI
Prior art keywords
compound
formula
alkyl
group
mmol
Prior art date
Application number
OA9800061A
Other languages
English (en)
Inventor
Giuseppe Amaldo Maria
Mario Grugni
Luca Francesco Raeglia
Carlo Farina
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95MI002461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of OA11010A publication Critical patent/OA11010A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA9800061A 1995-11-24 1998-05-22 Quinoline derivatives OA11010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI002461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici

Publications (1)

Publication Number Publication Date
OA11010A true OA11010A (en) 2003-03-06

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800061A OA11010A (en) 1995-11-24 1998-05-22 Quinoline derivatives

Country Status (26)

Country Link
US (1) US6277862B1 (xx)
EP (1) EP0876347B1 (xx)
JP (1) JP2000501104A (xx)
KR (1) KR19990071597A (xx)
CN (1) CN1207730A (xx)
AP (1) AP9801237A0 (xx)
AR (1) AR004972A1 (xx)
AT (1) ATE289994T1 (xx)
BG (1) BG102558A (xx)
BR (1) BR9611820A (xx)
CA (1) CA2238298A1 (xx)
CZ (1) CZ157998A3 (xx)
DE (1) DE69634416T2 (xx)
EA (1) EA002124B1 (xx)
ES (1) ES2236757T3 (xx)
IL (1) IL124522A0 (xx)
MX (1) MX9804107A (xx)
NO (1) NO311212B1 (xx)
NZ (1) NZ323387A (xx)
OA (1) OA11010A (xx)
PL (1) PL326967A1 (xx)
SK (1) SK66798A3 (xx)
TR (1) TR199800924T2 (xx)
TW (1) TW353066B (xx)
UY (1) UY24733A1 (xx)
WO (1) WO1997021680A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290470B6 (cs) * 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038600A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
ATE318266T1 (de) * 2001-04-11 2006-03-15 Glaxosmithkline Spa 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
JP4584911B2 (ja) 2003-01-28 2010-11-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド 胃腸障害の治療のための方法および組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303086D0 (en) * 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
EP1812383A1 (en) * 2004-11-09 2007-08-01 Smithkline Beecham Corporation Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
US20080287492A1 (en) * 2005-08-11 2008-11-20 Astrazeneca Ab Alkylpyridyl Quinolines as Nk3 Receptor Modulators
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
MX2010003440A (es) * 2007-09-28 2010-04-21 Glaxosmithkline Llc Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
WO2009045831A1 (en) * 2007-09-28 2009-04-09 Smithkline Beecham Corporation Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20150336892A1 (en) 2012-08-21 2015-11-26 Ardelyx, Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3552630A1 (en) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-binding compounds for inhibiting phosphate transport
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS63119455A (ja) * 1986-06-27 1988-05-24 Nippon Shinyaku Co Ltd グリシン誘導体
PL186665B1 (pl) * 1994-05-27 2004-02-27 Smithkline Beecham Spa Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
CN1207730A (zh) 1999-02-10
NO982331D0 (no) 1998-05-22
MX9804107A (es) 1998-09-30
WO1997021680A1 (en) 1997-06-19
ATE289994T1 (de) 2005-03-15
EA199800477A1 (ru) 1998-12-24
DE69634416T2 (de) 2005-12-29
AP9801237A0 (en) 1998-06-30
EP0876347B1 (en) 2005-03-02
EP0876347A1 (en) 1998-11-11
BR9611820A (pt) 1999-07-13
CA2238298A1 (en) 1997-06-19
NO311212B1 (no) 2001-10-29
BG102558A (bg) 1999-03-31
PL326967A1 (en) 1998-11-09
NZ323387A (en) 2000-02-28
IL124522A0 (en) 1998-12-06
AR004972A1 (es) 1999-04-07
CZ157998A3 (cs) 1998-12-16
US6277862B1 (en) 2001-08-21
JP2000501104A (ja) 2000-02-02
UY24733A1 (es) 2001-08-27
TW353066B (en) 1999-02-21
KR19990071597A (ko) 1999-09-27
TR199800924T2 (xx) 1998-08-21
NO982331L (no) 1998-07-22
ES2236757T3 (es) 2005-07-16
SK66798A3 (en) 1999-01-11
EA002124B1 (ru) 2001-12-24
DE69634416D1 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
OA11010A (en) Quinoline derivatives
WO1997021680A9 (en) Quinoline derivatives
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
EP0804419B1 (en) Quinoline derivatives as tachykinin nk 3 receptor antagonists
US20020068827A1 (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
WO1996002509A1 (en) Quinoline derivatives as nk3 antagonists
EP1377555B1 (en) A dioxino[2,3-g]quinoline-9-carboxylic acid derivative as nk3 receptor antagonist
EP0983262B1 (en) Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
EP1131294B1 (en) Quinoline derivatives as nk-2 and nk-3 receptor ligands
AU1031797A (en) Quinoline derivatives
AU757836B2 (en) Quinoline derivatives
US20030004183A1 (en) Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
NZ500371A (en) NK-2/NK-3 antagonists and their use in treating respiratory disease
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
CZ416199A3 (cs) Chinolin-4-karboxamidové deriváty jako antagonisté receptoru pro NK-2 a NK-3
KR20010012823A (ko) Nk-2 및 nk-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체